Edwards Lifesciences (EW) Tops Q3 EPS by 9c, Q4 & FY Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Edwards Lifesciences Reports Third Quarter Results
October 26, 2015 4:15 PM EDTIRVINE, Calif., Oct. 26, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported financial results for the quarter ended September 30, 2015.
Highlights for the third quarter of 2015 as compared to the third quarter of 2014:
Global sales grew 1.3% to $615.5 million, and underlying1 sales were up 13.6%. Global THV sales grew 10.8% to $296.1 million, and underlying sales were up 29.4%. The U.S. rollout of the Edwards SAPIEN 3... More